David Bonita | Private Equity Partner
Orbimed Advisors

David Bonita, Private Equity Partner, Orbimed Advisors

David Bonita, M.D., is a Private Equity Partner. Prior to joining OrbiMed, Dr. Bonita worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS. He has also published scientific articles in peer reviewed journals based on signal transduction research performed at the Harvard Medical School. Dr. Bonita received his A.B. degree magna cum laude in Biological Sciences from Harvard University and his joint M.D./M.B.A. from Columbia University where he was elected to the Alpha Omega Alpha Medical Honor Society and Beta Gamma Sigma Business Honor Society.


World Orphan Drug Congress USA 2018 - Conference Day One @ 11:25

VC Panel: Investing in the orphan drug space – derisking commercial models and driving biotechs to successful launches

  • Assessing advanced therapies commercial opportunities – and risks – as the new frontier of investment in rare disease companies
  • Type of work and diligence to obtain comfort with the ultimate market opportunity
  • Assessing barriers to entry including therapeutic modality and IP
  • Regulators role in incentivizing or impeding the ability to develop products both domestically and abroad. What can be different?

back to speakers